Worldwide Clinical Trials has enhanced its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, with a significant expansion completed in January 2024. The upgrade is part of a $5 million project to elevate the CPU, focusing on streamlining processes and reducing timelines and costs for clients. The expansion prioritizes equipment modernization, operational and workplace demand, as well as employee engagement—all aimed at enriching the customer experience.
Mike Mencer, Executive Vice President and General Manager of Early Phase at Worldwide, conveyed the team’s passion for cultivating customer relations and the alignment of the expansion with the company’s commitment to quality, continuous improvement, and innovation. The enhancements made to the pharmacy include the replacement of out-of-date equipment and a structural increase to bolster production capacity.
Lona Sheeran, Sr. Vice President of Clinical Operations, Early Phase, emphasized that the expanded size allows for greater volume handling, providing benefits such as in-house, real-time manufacturing for Phase 1 studies as per FDA guidance. This unique offering presents significant cost and time savings for clients, a crucial advantage in the dynamic and fast-paced clinical research sector.
Worldwide’s CPU, operational since 2005, is a state-of-the-art facility equipped to conduct studies involving healthy volunteers, patients, and specialty populations, boasting a 200-bed capacity. Its proximity to Worldwide’s Bioanalytical Center of Excellence allows for a cohesive approach that offers clients consistent standards, expertise, and increased efficiency in terms of vendor management and sample processing.
For more information on the CPU and Bioanalytical Center of Excellence, including virtual tours of both facilities, Worldwide has provided online resources. The expansion of Worldwide’s CPU signifies their dedication to advancing clinical research and improving patient outcomes on a global scale.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
